HIV lipodystrophy syndrome: A primer

Journal of the Association of Nurses in AIDS Care

Volumn 15, Issue 1, 2004, Pages 15-29

  Robinson, F Patrick ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Antiretroviral therapy; HIV AIDS; Lipodystrophy; Metabolic abnormalities

Indexed keywords

ANTIRETROVIRUS AGENT; FIBRIC ACID DERIVATIVE; HUMAN GROWTH HORMONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; PROTEINASE INHIBITOR;

DYSLIPIDEMIA; EXERCISE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LIPODYSTROPHY; HORMONE SUBSTITUTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSULIN RESISTANCE; LIPOSUCTION; NURSING; PATIENT COUNSELING; PATIENT EDUCATION; PREVALENCE; REVIEW; BODY IMAGE; EVIDENCE BASED MEDICINE; KINESIOTHERAPY; METABOLISM; NURSE ATTITUDE; PATIENT COMPLIANCE; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; RISK FACTOR; TREATMENT OUTCOME;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BODY IMAGE; EVIDENCE-BASED MEDICINE; EXERCISE THERAPY; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; INSULIN RESISTANCE; NURSE'S ROLE; PATIENT COMPLIANCE; PATIENT EDUCATION; PREVALENCE; QUALITY OF LIFE; RISK FACTORS; TREATMENT OUTCOME;

EID: 1542529831     PISSN: 10553290     EISSN: None     Source Type: Journal    
DOI: 10.1177/1055329003255117     Document Type: Article

References (165)

1. Acevedo, M., Sprecher, D. L., Calabrese, L., Pearce, G. L., Coyner, D. L., Halliburton, S. S., et al. (2002). Pilot study of coronary atherosclerotic risk and plaque burden in HIV patients: "A call for cardiovascular prevention." Atherosclerosis, 163(2), 349-354.
2. American College of Sports Medicine, & Roitman, J. L. (2001). ACSM's resource manual for guidelines for exercise testing and prescription (4th ed.). Baltimore: Lippincott Williams & Wilkins.
3. Assmann, G., & Schulte, H. (1992a). Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). American Journal of Cardiology, 70(7), 733-737.
4. Assmann, G., & Schulte, H. (1992b). Role of triglycerides in coronary artery disease: Lessons from the Prospective Cardiovascular Study. American Journal of Cardiology, 70(19), 10H-13H.
5. Baldini, F., Di Giambenedetto, S., Cingolani, A., Murri, R., Ammassari, A., & De Luca, A. (2000). Efficacy and tolerability of pravastatin for the treatment of HIV-1 protease inhibitor-associated hyperlipidaemia: A pilot study. AIDS, 14(11), 1660-1662.
6. Bangsberg, D. R., Hecht, F. M., Charlebois, E. D., Zolopa, A. R., Holodniy, M., Sheiner, L., et al. (2000). Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS, 14(4), 357-366.
7. Bassett, D. R., Jr. (1994). Skeletal muscle characteristics: Relationships to cardiovascular risk factors. Medicine & Science in Sports & Exercise, 26(8), 957-966.
8. Beckman, J. A., Creager, M. A., & Libby, P. (2002). Diabetes and atherosclerosis: Epidemiology, pathophysiology, and management. Journal of the American Medical Association, 287(19), 2570-2581.
9. Berthold, H. K., Parhofer, K. G., Ritter, M. M., Addo, M., Wasmuth, J. C., Schliefer, K., et al. (1999). Influence of protease inhibitor therapy on lipoprotein metabolism. Journal of Internal Medicine, 246(6), 567-575.
10. Brinkman, K., Smeitink, J. A., Romijn, J. A., & Reiss, P. (1999). Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy [letter; comment] [see comments]. Lancet, 354(9184), 1112-1115.
11. Buemann, B., & Tremblay, A. (1996). Effects of exercise training on abdominal obesity and related metabolic complications. Sports Medicine, 21(3), 191-212.
12. Burres, S. (2001). Soft-tissue augmentation with Fascian. Clinics in Plastic Surgery, 28(1), 101-110.
13. Carr, A., Hudson, J., Chuah, J., Mallal, S., Law, M., Hoy, J., et al. (2001). HIV protease inhibitor substitution in patients with lipodystrophy: A randomized, controlled, open-label, multicentre study. AIDS, 15(14), 1811-1822.
14. Carr, A., Samaras, K., Burton, S., Law, M., Freund, J., Chisholm, D. J., et al. (1998). A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS, 12(7), F51-F58.
15. Carr, A., Samaras, K., Chisholm, D. J., & Cooper, D. A. (1998a). Abnormal fat distribution and use of protease inhibitors [letter; comment]. Lancet, 351(9117), 1736.
16. Carr, A., Samaras, K., Chisholm, D. J., & Cooper, D. A. (1998b). Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet, 351(9119), 1881-1883.
17. Carr, A., Samaras, K., Thorisdottir, A., Kaufmann, G. R., Chisholm, D. J., & Cooper, D. A. (1999). Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: A cohort study [see comments]. Lancet, 353(9170), 2093-2099.
18. Carr, A., Workman, C., Smith, D. E., Hoy, J., Hudson, J., Doong, N., et al. (2002). Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: A randomized trial. Journal of the American Medical Association, 288(2), 207-215.
19. Chastain, M. A., Chastain, J. B., & Coleman, W. P. (2001). HIV lipodystrophy: Review of the syndrome and report of a case treated with liposuction [see comments]. Dermatologic Surgery, 27(5), 497-500.
20. Chattha, G., Arieff, A. I., Cummings, C., & Tierney, L. M., Jr. (1993). Lactic acidosis complicating the acquired immunodeficiency syndrome [see comments]. Annals of Internal Medicine, 118(1), 37-39.
21. Chen, C. H., Vazquez-Padua, M., & Cheng, Y. C. (1991). Effect of anti-human immunodeficiency virus nucleoside analogs on mitochondrial DNA and its implication for delayed toxicity. Molecular Pharmacology, 39(5), 625-628.
22. Chiesi, A., Mocroft, A., Dally, L. G., Miller, V., Katlama, C., Ledergerber, B., et al. (1999). Regional survival differences across Europe in HIV-positive people: The EuroSIDA study. AIDS, 13(16), 2281-2288.
23. Christeff, N., Melchior, J. C., de Truchis, P., Perronne, C., & Gougeon, M. L. (2002). Increased serum interferon alpha in HIV-1 associated lipodystrophy syndrome. European Journal of Clinical Investigation, 32(1), 43-50.
24. Cleeman, J. I., & Lenfant, C. (1998). The National Cholesterol Education Program: Progress and prospects. JAMA, 280(24), 2099-2104.
25. Collins, E., Wagner, C., & Walmsley, S. (2000). Psychosocial impact of the lipodystrophy syndrome in HIV infection. AIDS Reader, 10(9), 546-550.
26. Craig, B. W., Everhart, J., & Brown, R. (1989). The influence of high-resistance training on glucose tolerance in young and elderly subjects. Mechanisms of Ageing & Development, 49(2), 147-157.
27. David, M. H., Hornung, R., & Fichtenbaum, C. J. (2002). Ischemic cardiovascular disease in persons with human immunodeficiency virus infection. Clinical Infectious Diseases, 34(1), 98-102.
28. Deedwania, P. (1998). The deadly quartet revisted. American Journal of Medicine, 105, S1-S3.
29. Deeks, S. G. (2000). Determinants of virological response to antiretroviral therapy: Implications for long-term strategies. Clinical Infectious Diseases, 30(Suppl. 2), S177-S184.
30. DeFronzo, R. A. (1992). Insulin resistance, hyperinsulinemia, and coronary artery disease: A complex metabolic web. Journal of Cardiovascular Pharmacology, 20(Suppl. 11), S1-S16.
31. Donahue, R. P. (1987). Postchallenge glucose concentration and coronary heart disease in men of Japanese ancestry. Honolulu Heart Program. Diabetes, 36(6), 689-692.
32. Dong, K. L., Bausserman, L. L., Flynn, M. M., Dickinson, B. P., Flanigan, T. P., Mileno, M. D., et al. (1999). Changes in body habitus and serum lipid abnormalities in HIV-positive women on highly active antiretroviral therapy (HAART). Journal of Acquired Immune Deficiency Syndromes, 21(2), 107-113.
33. Duong, M., Buisson, M., Cottin, Y., Piroth, L., Lhuillier, I., Grappin, M., et al. (2001). Coronary heart disease associated with the use of human immunodeficiency virus (HIV)-1 protease inhibitors: Report of four cases and review. Clinical Cardiology, 24(10), 690-694.
34. Durstine, J. L., Grandjean, P. W., Davis, P. G., Ferguson, M. A., Alderson, N. L., & DuBose, K. D. (2001). Blood lipid and lipoprotein adaptations to exercise: A quantitative analysis. Sports Medicine, 31(15), 1033-1062.
35. Endre, T., Mattiasson, I., Hulthen, U. L., Lindgarde, F., & Berglund, G. (1994). Insulin resistance is coupled to low physical fitness in normotensive men with a family history of hypertension. Journal of Hypertension, 12(1), 81-88.
36. Engelson, E. S., Glesby, M. J., Mendez, D., Albu, J. B., Wang, J., Heymsfield, S. B., et al. (2002). Effect of recombinant human growth hormone in the treatment of visceral fat accumulation in HIV infection. JAIDS Journal of Acquired Immune Deficiency Syndromes, 30(4), 379-391.
37. Estrada, V., Serrano-Rios, M., Martinez Larrad, M. T., Villar, N. G., Gonzalez Lopez, A., Tellez, M. J., et al. (2002). Leptin and adipose tissue maldistribution in HIV-infected male patients with predominant fat loss treated with antiretroviral therapy. Journal of Acquired Immune Deficiency Syndromes, 29(1), 32-40.
38. Expert Panel on Detection, Education, & Treatment of High Blood Cholesterol in Adults. (2001). Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) [see comments]. Journal of the American Medical Association, 285(19), 2486-2497.
39. Fagan, T., & Deedwania, P. (1998). Syndrome X: 6 years later. American Journal of Medicine, 105, S77-S82.
40. Fedder, D. O., Koro, C. E., & L'Italien, G. J. (2002). New National Cholesterol Education Program III guidelines for primary prevention lipid-lowering drug therapy: Projected impact on the size, sex, and age distribution of the treatment-eligible population [see comments]. Circulation, 105(2), 152-156.
41. Feskens, E. J., Loeber, J. G., & Kromhout, D. (1994). Diet and physical activity as determinants of hyperinsulinemia: The Zutphen Elderly Study. American Journal of Epidemiology, 140(4), 350-360.
42. Fortgang, I. S., Belitsos, P. C., Chaisson, R. E., & Moore, R. D. (1995). Hepatomegaly and steatosis in HIV-infected patients receiving nucleoside analog antiretroviral therapy. American Journal of Gastroenterology, 90(9), 1433-1436.
43. Gallet, B., Pulik, M., Genet, P., Chedin, P., & Hiltgen, M. (1998). Vascular complications associated with use of HIV protease inhibitors [letter; comment]. Lancet, 351(9120), 1958-1959.
44. Galli, M., Cozzi-Lepri, A., Ridolfo, A. L., Gervasoni, C., Ravasio, L., Corsico, L., et al. (2002). Incidence of adipose tissue alterations in first-line antiretroviral therapy: The LipoICoNa Study. Archives of Internal Medicine, 162(22), 2621-2628.
45. Gelato, M. C., Mynarcik, D. C., Quick, J. L., Steigbigel, R. T., Fuhrer, J., Brathwaite, C. E., et al. (2002). Improved insulin sensitivity and body fat distribution in HIV-infected patients treated with rosiglitazone: A pilot study. Journal of Acquired Immune Deficiency Syndromes, 31(2), 163-170.
46. Geletko, S. M., & ZuWallack, A. R. (2001). Treatment of hyperlipidemia in HIV-infected patients. American Journal of Health-System Pharmacy, 58(7), 607-614.
47. Gervasoni, C., Ridolfo, A. L., Trifiro, G., Santambrogio, S., Norbiato, G., Musicco, M., et al. (1999). Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy. AIDS, 13(4), 465-471.
48. Glazer, G. (1991). Atherogenic effects of anabolic steroids on serum lipid levels. A literature review. Archives of Internal Medicine, 151(10), 1925-1933. [Erratum appears in Archives of Internal Medicine 1992 Mar;152(3):535]
49. Gold, J., & Batterham, M. (1999). Nandrolone decanoate; use in HIV-associated lipodystrophy syndrome: A pilot study. International Journal of STD & AIDS, 10(8), 558.
50. Grinspoon, S. (2001). Insulin resistance in the HIV-lipodystrophy syndrome. Trends in Endocrinology & Metabolism, 12(9), 413-419.
51. Grunfeld, C., Kotler, D. P., Hamadeh, R., Tierney, A., Wang, J., & Pierson, R. N. (1989). Hypertriglyceridemia in the acquired immunodeficiency syndrome. American Journal of Medicine, 86(1), 27-31.
52. Hadigan, C., Borgonha, S., Rabe, J., Young, V., & Grinspoon, S. (2002). Increased rates of lipolysis among human immunodeficiency virus-infected men receiving highly active antiretroviral therapy. Metabolism: Clinical & Experimental, 51(9), 1143-1147.
53. Hadigan, C., Corcoran, C., Basgoz, N., Davis, B., Sax, P., & Grinspoon, S. (2000). Metformin in the treatment of HIV lipodystrophy syndrome: A randomized controlled trial. Journal of the American Medical Association, 284(4), 472-477.
54. Hadigan, C., Corcoran, C., Stanley, T., Piecuch, S., Klibanski, A., & Grinspoon, S. (2000). Fasting hyperinsulinemia in human immunodeficiency virus-infected men: Relationship to body composition, gonadal function, and protease inhibitor use. Journal of Clinical Endocrinology & Metabolism, 85(1), 35-41.
55. Hadigan, C., Meigs, J. B., Corcoran, C., Rietschel, P., Piecuch, S., Basgoz, N., et al. (2001). Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clinical Infectious Diseases, 32(1), 130-139.
56. Hadigan, C., Miller, K., Corcoran, C., Anderson, E., Basgoz, N., & Grinspoon, S. (1999). Fasting hyperinsulinemia and changes in regional body composition in human immunodeficiency virus-infected women. Journal of Clinical Endocrinology & Metabolism, 84(6), 1932-1937.
57. Hadigan, C., Rabe, J., & Grinspoon, S. (2002). Sustained benefits of metformin therapy on markers of cardiovascular risk in human immunodeficiency virus-infected patients with fat redistribution and insulin resistance. Journal of Clinical Endocrinology & Metabolism, 87(10), 4611-4615.
58. Halbert, J. A., Silagy, C. A., Finucane, P., Withers, R. T., & Hamdorf, P. A. (1999). Exercise training and blood lipids in hyperlipidemic and normolipidemic adults: A meta-analysis of randomized, controlled trials. European Journal of Clinical Nutrition, 53(7), 514-522.
59. Heath, K. V., Chan, K. J., Singer, J., O'Shaughnessy, M. V., Montaner, J. S., & Hogg, R. S. (2002). Incidence of morphological and lipid abnormalities: Gender and treatment differentials after initiation of first antiretroviral therapy. International Journal of Epidemiology, 31(5), 1016-1020.
60. Heath, K. V., Hogg, R. S., Chan, K. J., Harris, M., Montessori, V., O'Shaughnessy, M. V., et al. (2001). Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV/AIDS treatment database [see comments]. AIDS, 15(2), 231-239.
61. Heath, K. V., Hogg, R. S., Singer, J., Chan, K. J., O'Shaughnessy, M. V., & Montaner, J. S. (2002). Antiretroviral treatment patterns and incident HIV-associated morphologic and lipid abnormalities in a population-based cohort. Journal of Acquired Immune Deficiency Syndromes, 30, 440-447.
62. Henry, K., Melroe, H., Huebesch, J., Hermundson, J., Levine, C., Swensen, L., et al. (1998). Severe premature coronary artery disease with protease inhibitors [see comments]. Lancet, 351(9112), 1328.
63. Henry, K., Melroe, H., Huebesch, J., Hermundson, J., & Simpson, J. (1998). Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalities [see comments]. Lancet, 352(9133), 1031-1032.
64. Hewitt, R. G., Shelton, M. J., & Esch, L. D. (1999). Gemfibrozil effectively lowers protease inhibitor-associated hypertriglyceridemia in HIV-1-positive patients. AIDS, 13(7), 868-869.
65. Hodgson, J. M., Wahlqvist, M. L., Balazs, N. D., & Boxall, J. A. (1994). Coronary atherosclerosis in relation to body fatness and its distribution. International Journal of Obesity & Related Metabolic Disorders, 18(1), 41-46.
66. Holmberg, S. D., Moorman, A. C., Williamson, J. M., Tong, T. C., Ward, D. J., Wood, K. C., et al. (2002). protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet, 360, 1747-1748.
67. Huang, J. S., Rietschel, P., Hadigan, C. M., Rosenthal, D. I., & Grinspoon, S. (2001). Increased abdominal visceral fat is associated with reduced bone density in HIV-infected men with lipodystrophy. AIDS, 15(8), 975-982.
68. Hurley, B. F., Hagberg, J. M., Allen, W. K., Seals, D. R., Young, J. C., Cuddihee, R. W., et al. (1984). Effect of training on blood lactate levels during submaximal exercise. Journal of Applied Physiology: Respiratory, Environmental & Exercise Physiology, 56(5), 1260-1264.
69. Ivy, J. L. (1997). Role of exercise training in the prevention and treatment of insulin resistance and non-insulin-dependent diabetes mellitus. Sports Medicine, 24(5), 321-336.
70. James, J., Carruthers, A., & Carruthers, J. (2002). HIV-associated facial lipoatrophy. Dermatologic Surgery, 28(11), 979-986.
71. Jennings, G., Nelson, L., Nestel, P., Esler, M., Korner, P., Burton, D., et al. (1986). The effects of changes in physical activity on major cardiovascular risk factors, hemodynamics, sympathetic function, and glucose utilization in man: A controlled study of four levels of activity. Circulation, 73(1), 30-40.
72. Jones, S. P., Doran, D. A., Leatt, P. B., Maher, B., & Pirmohamed, M. (2001). Short-term exercise training improves body composition and hyperlipidaemia in HIV-positive individuals with lipodystrophy. AIDS, 15(15), 2049-2051.
73. Kannel, W. B. (1979). Cholesterol in the prediction of atherosclerotic disease. New perspectives based on the Framingham study. Annals of Internal Medicine, 90(1), 85-91.
74. Keil, U. (2000). Coronary artery disease: The role of lipids, hypertension and smoking. Basic Research in Cardiology, 95(Suppl. 1), I52-I58.
75. Klein, A. W., & Rish, D. C. (1985). Substances for soft tissue augmentation: Collagen and silicone. Journal of Dermatologic Surgery & Oncology, 11(3), 337-339.
76. Knobel, H., Guelar, A., Vallecillo, G., Nogues, X., & Diez, A. (2001). Osteopenia in HIV-infected patients: Is it the disease or is it the treatment? AIDS, 15(6), 807-808.
77. Koppel, K., Bratt, G., Eriksson, M., & Sandstrom, E. (2000). Serum lipid levels associated with increased risk for cardiovascular disease is associated with highly active antiretroviral therapy (HAART) in HIV-1 infection. International Journal of STD & AIDS, 11(7), 451-455.
78. Kosmiski, L. A., Kuritzkes, D. R., Lichtenstein, K. A., Glueck, D. H., Gourley, P. J., Stamm, E. R., et al. (2001). Fat distribution and metabolic changes are strongly correlated and energy expenditure is increased in the HIV lipodystrophy syndrome [see comments]. AIDS, 15(15), 1993-2000.
79. Kotler, D. P., Rosenbaum, K., Wang, J., & Pierson, R. N. (1999). Studies of body composition and fat distribution in HIV-infected and control subjects. Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology, 20(3), 228-237.
80. Lamarche, B., Tchernof, A., Mauriege, P., Cantin, B., Dagenais, G. R., Lupien, P. J., et al. (1998). Fasting insulin and apolipoprotein B levels and low-density lipoprotein particle size as risk factors for ischemic heart disease [see comments]. JAMA, 279(24), 1955-1961.
81. Lawal, A., Engelson, E. S., Wang, J., Heymsfield, S. B., & Kotler, D. P. (2001). Equivalent osteopenia in HIV-infected individuals studied before and during the era of highly active antiretroviral therapy. AIDS, 15(2), 278-280.
82. Ledru, E., Christeff, N., Patey, O., de Truchis, P., Melchior, J. C., & Gougeon, M. L. (2000). Alteration of tumor necrosis factor-alpha T-cell homeostasis following potent antiretroviral therapy: Contribution to the development of human immunodeficiency virus-associated lipodystrophy syndrome. Blood, 95(10), 3191-3198. [Erratum appears in Blood 2000 Sep 1;96(5):1673]
83. Levine, G. N. (1995). Cholesterol reduction in cardiovascular disease. Clinical benefits and possible mechanisms [letter; comment]. New England Journal of Medicine, 332(8), 512-521.
84. Lichtenstein, K. A., Ward, D. J., Moorman, A. C., Delaney, K. M., Young, B., Palella, F. J., Jr., et al. (2001). Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. AIDS, 15(11), 1389-1398.
85. Lo, J. C., Mulligan, K., Noor, M. A., Schwarz, J. M., Halvorsen, R. A., Grunfeld, C., et al. (2001). The effects of recombinant human growth hormone on body composition and glucose metabolism in HIV-infected patients with fat accumulation [comment]. Journal of Clinical Endocrinology & Metabolism, 86(8), 3480-3487.
86. Lo, J. C., Mulligan, K., Tai, V. W., Algren, H., & Schambelan, M. (1998). "Buffalo hump" in men with HIV-1 infection [see comments]. Lancet, 351(9106), 867-870.
87. Madge, S. (1999). Lipodystrophy in patients naive to HIV protease inhibitors. AIDS, 13(6), 735-737.
88. Mallal, S. A., John, M., Moore, C. B., James, I. R., & McKinnon, E. J. (2000). Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS, 14(10), 1309-1316.
89. Manninen, V., Tenkanen, L., Koskinen, P., Huttunen, J. K., Manttari, M., Heinonen, O. P., et al. (1992). Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment [see comments]. Circulation, 85(1), 37-45.
90. Martinez, E., Conget, I., Lozano, L., Casamitjana, R., & Gatell, J. M. (1999). Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. AIDS, 1(7), 805-810.
91. Martinez, E., Garcia-Viejo, M. A., Blanco, J. L., Bianchi, L., Buira, E., Conget, I., et al. (2000). Impact of switching from human immunodeficiency virus type 1 protease inhibitors to efavirenz in successfully treated adults with lipodystrophy. Clinical Infectious Diseases, 31(5), 1266-1273.
92. Mauss, S., Corzillius, M., Wolf, E., Schwenk, A., Adam, A., Jaeger, H., et al. (2002). Risk factors for the HIV-associated lipodystrophy syndrome in a closed cohort of patients after 3 years of antiretroviral treatment. HIV Medicine, 3(1), 49-55.
93. McComsey, G., Tan, D. J., Lederman, M., Wilson, E., & Wong, L. J. (2002). Analysis of the mitochondrial DNA genome in the peripheral blood leukocytes of HIV-infected patients with or without lipoatrophy. AIDS, 16(4), 513-518.
94. Medina, D. J., Tsai, C. H., Hsiung, G. D., & Cheng, Y. C. (1994). Comparison of mitochondrial morphology, mitochondrial DNA content, and cell viability in cultured cells treated with three anti-human immunodeficiency virus dideoxynucleosides. Antimicrobial Agents & Chemotherapy, 38(8), 1824-1828.
95. Meienberg, F., Battegay, E., Bucher, H. C., & Battegay, M. (2001). The use of lipid-lowering agents in HIV-infected patients [see comments]. Journal of HIV Therapy, 6(2), 40-44.
96. Meininger, G., Hadigan, C., Rietschel, P., & Grinspoon, S. (2002). Body-composition measurements as predictors of glucose and insulin abnormalities in HIV-positive men. American Journal of Clinical Nutrition, 76(2), 460-465.
97. Mercie, P., Thiebaut, R., Lavignolle, V., Pellegrin, J. L., Yvorra-Vives, M. C., Morlat, P., et al. (2002). Evaluation of cardiovascular risk factors in HIV-1 infected patients using carotid intima-media thickness measurement. Annals of Medicine, 34, 55-63.
98. Miller, J. P., Pratley, R. E., Goldberg, A. P., Gordon, P., Rubin, M., Treuth, M. S., et al. (1994). Strength training increases insulin action in healthy 50- to 65-yr-old men. Journal of Applied Physiology, 77(3), 1122-1127.
99. Miller, K. D., Jones, E., Yanovski, J. A., Shankar, R., Feuerstein, I., & Falloon, J. (1998). Visceral abdominal-fat accumulation associated with use of indinavir [see comments]. Lancet, 351(9106), 871-875.
100. Miller, W. J., Sherman, W. M., & Ivy, J. L. (1984). Effect of strength training on glucose tolerance and post-glucose insulin response. Medicine & Science in Sports & Exercise, 16(6), 539-543.
101. Muise, A., & Arbess, G. (2001). The risk of myocardial infarction in HIV-infected patients receiving HAART: A case report. International Journal of STD & AIDS, 12(9), 612-613.
102. Mulligan, K., Grunfeld, C., Tai, V. W., Algren, H., Pang, M., Chernoff, D. N., et al. (2000). Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection [see comments]. Journal of Acquired Immune Deficiency Syndromes, 23(1), 35-43.
103. Murillas, J., Martin, T., Ramos, A., & Portero, J. L. (1999). Atorvastatin for protease inhibitor-related hyperlipidaemia. AIDS, 13(11), 1424-1425.
104. Mynarcik, D. C., McNurlan, M. A., Steigbigel, R. T., Fuhrer, J., & Gelato, M. C. (2000). Association of severe insulin resistance with both loss of limb fat and elevated serum tumor necrosis factor receptor levels in HIV lipodystrophy. Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology, 25(4), 312-321.
105. Negredo, E., Ribalta, J., Paredes, R., Ferre, R., Sirera, G., Ruiz, L., et al. (2002). Reversal of atherogenic lipoprotein profile in HIV-1 infected patients with lipodystrophy after replacing protease inhibitors by nevirapine. AIDS, 16(10), 1383-1389.
106. Nixon, S., O'Brien, K., Glazier, R. H., & Wilkins, A. L. (2001). Aerobic exercise interventions for people with HIV/AIDS. Cochrane Database of Systematic Reviews (1), CD001796.
107. O'Mahony, C., Price, L. M., & Nelson, M. (1998). Lipodystrophy despite anabolic steroids. International Journal of STD & AIDS, 9(10), 619.
108. Oshida, Y., Yamanouchi, K., Hayamizu, S., & Sato, Y. (1989). Long-term mild jogging increases insulin action despite no influence on body mass index or VO2 max. Journal of Applied Physiology, 66(5), 2206-2210.
109. Palella, F. J., Delaney, K. M., Moorman, A. C., Loveless, M. O., Fuhrer, J., Satten, G. A., et al. (1998). Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators [see comments]. New England Journal of Medicine, 338(13), 853-860.
110. Penzak, S. R., & Chuck, S. K. (2000). Hyperlipidemia associated with HIV protease inhibitor use: Pathophysiology, prevalence, risk factors and treatment. Scandinavian Journal of Infectious Diseases, 32(2), 111-123.
111. Penzak, S. R., Chuck, S. K., & Stajich, G. V. (2000). Safety and efficacy of HMG-CoA reductase inhibitors for treatment of hyperlipidemia in patients with HIV infection. Pharmacotherapy, 20(9), 1066-1071.
112. Periard, D., Telenti, A., Sudre, P., Cheseaux, J. J., Halfon, P., Reymond, M. J., et al. (1999). Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. Circulation, 100(7), 700-705.
113. Pollack, S. V. (1990). Silicone, fibrel, and collagen implantation for facial lines and wrinkles. Journal of Dermatologic Surgery & Oncology, 16(10), 957-961.
114. Ponce-de-Leon, S., Iglesias, M., Ceballos, J., & Ostrosky-Zeichner, L. (1999). Liposuction for protease-inhibitor-associated lipodystrophy. Lancet, 353(9160), 1244.
115. Reaven, G. M. (1988). Banting lecture 1988. Role of insulin resistance in human disease. Diabetes, 37(12), 1595-1607.
116. Regensteiner, J. G., Mayer, E. J., Shetterly, S. M., Eckel, R. H., Haskell, W. L., Marshall, J. A., et al. (1991). Relationship between habitual physical activity and insulin levels among nondiabetic men and women. San Luis Valley Diabetes Study. Diabetes Care, 14(11), 1066-1074.
117. Ridolfo, A. L., Gervasoni, C., Bini, T., & Galli, M. (2000). Body habitus alterations in HIV-infected women treated with combined antiretroviral therapy. AIDS Patient Care & Stds, 14(11), 595-601.
118. Rietschel, P., Hadigan, C., Corcoran, C., Stanley, T., Neubauer, G., Gertner, J., et al. (2001). Assessment of growth hormone dynamics in human immunodeficiency virus-related lipodystrophy. Journal of Clinical Endocrinology & Metabolism, 86(2), 504-510.
119. Rosenbaum, M., & Leibel, R. L. (1999). The role of leptin in human physiology [letter; comment]. New England Journal of Medicine, 341(12), 913-915.
120. Rosenthal, M., Haskell, W. L., Solomon, R., Widstrom, A., & Reaven, G. M. (1983). Demonstration of a relationship between level of physical training and insulin-stimulated glucose utilization in normal humans. Diabetes, 32(5), 408-411.
121. Roth, V. R., Kravcik, S., & Angel, J. B. (1998). Development of cervical fat pads following therapy with human immunodeficiency virus type 1 protease inhibitors [see comments]. Clinical Infectious Diseases, 27(1), 65-67.
122. Roubenoff, R., Skolnik, P. R., Shevitz, A., Snydman, L., Wang, A., Melanson, S., et al. (1999). Effect of a single bout of acute exercise on plasma human immunodeficiency virus RNA levels. Journal of Applied Physiology, 86(4), 1197-1201.
123. Roubenoff, R., Weiss, L., McDermott, A., Heflin, T., Cloutier, G. J., Wood, M., et al. (1999). A pilot study of exercise training to reduce trunk fat in adults with HIV-associated fat redistribution. AIDS, 13(11), 1373-1375.
124. Safrin, S., & Grunfeld, C. (1999). Fat distribution and metabolic changes in patients with HIV infection. AIDS, 13(18), 2493-2505.
125. Saint-Marc, T., Partisani, M., Poizot-Martin, I., Bruno, F., Rouviere, O., Lang, J. M., et al. (1999). A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy [see comments]. AIDS, 13(13), 1659-1667.
126. Saint-Marc, T., Partisani, M., Poizot-Martin, I., Rouviere, O., Bruno, F., Avellaneda, R., et al. (2000). Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: Preliminary results of the LIPOCO study. AIDS, 14(1), 37-49.
127. Saint-Marc, T., & Touraine, J. L. (1999). Effects of metformin on insulin resistance and central adiposity in patients receiving effective protease inhibitor therapy. AIDS, 13(8), 1000-1002.
128. Sattler, F. R., Qian, D., Louie, S., Johnson, D., Briggs, W., DeQuattro, V., et al. (2001). Elevated blood pressure in subjects with lipodystrophy. AIDS, 15(15), 2001-2010.
129. Saves, M., Raffi, F., Capeau, J., Rozenbaum, W., Ragnaud, J. M., Perronne, C., et al. (2002). Factors related to lipodystrophy and metabolic alterations in patients with human immunodeficiency virus infection receiving highly active antiretroviral therapy. Clinical Infectious Diseases, 34(10), 1396-1405.
130. Schambelan, M., Benson, C. A., Carr, A., Currier, J. S., Dube, M. P., Gerber, J. G., et al. (2002). Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: Recommendations of an International AIDS Society-USA panel. Journal of Acquired Immune Deficiency Syndromes, 31(3), 257-275.
131. Schwartz, R. S., Shuman, W. P., Larson, V., Cain, K. C., Fellingham, G. W., Beard, J. C., et al. (1991). The effect of intensive endurance exercise training on body fat distribution in young and older men. Metabolism: Clinical & Experimental, 40(5), 545-551.
132. Schwenk, A. (2002). Methods of assessing body shape and composition in HIV-associated lipodystrophy. Current Opinion in Infectious Diseases, 15(1), 9-16.
133. Seals, D. R., Hagberg, J. M., Hurley, B. F., Ehsani, A. A., & Holloszy, J. O. (1984). Effects of endurance training on glucose tolerance and plasma lipid levels in older men and women. Journal of the American Medical Association, 252(5), 645-649.
134. Sellmeyer, D. E., & Grunfeld, C. (1996). Endocrine and metabolic disturbances in human immunodeficiency virus infection and the acquired immune deficiency syndrome. Endocrine Reviews, 17(5), 518-532.
135. Shevitz, A. (2001). Clinical perspectives on HIV-associated lipodystrophy syndrome: An update. AIDS, 15(15), 1917-1930.
136. Shore, J. W. (1999). Injectable lyophilized particulate human fascia lata (Fascian) for lip, perioral, and glabellar enhancement. Ophthalmic Plastic and Reconstructive Surgery, 16, 23-27.
137. Simoneau, J. A., Colberg, S. R., Thaete, F. L., & Kelley, D. E. (1995). Skeletal muscle glycolytic and oxidative enzyme capacities are determinants of insulin sensitivity and muscle composition in obese women. FASEB Journal, 9(2), 273-278.
138. Smith, B. A., Neidig, J. L., Nickel, J. T., Mitchell, G. L., Para, M. F., & Fass, R. J. (2001). Aerobic exercise: Effects on parameters related to fatigue, dyspnea, weight and body composition in HIV-infected adults. AIDS, 15(6), 693-701.
139. Smutok, M. A., Reece, C., Kokkinos, P. F., Farmer, C., Dawson, P., Shulman, R., et al. (1993). Aerobic versus strength training for risk factor intervention in middle-aged men at high risk for coronary heart disease. Metabolism: Clinical & Experimental, 42(2), 177-184.
140. Smutok, M. A., Reece, C., Kokkinos, P. F., Farmer, C. M., Dawson, P. K., DeVane, J., et al. (1994). Effects of exercise training modality on glucose tolerance in men with abnormal glucose regulation. International Journal of Sports Medicine, 15(6), 283-289.
141. Stampfer, M. J., Krauss, R. M., Ma, J., Blanche, P. J., Holl, L. G., Sacks, F. M., et al. (1996). A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction [see comments]. Journal of the American Medical Association, 276(11), 882-888.
142. Stein, J. H., Klein, M. A., Bellehumeur, J. L., McBride, P. E., Wiebe, D. A., Otvos, J. D., et al. (2001). Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation, 104(3), 257-262.
143. Struble, K., & Piscitelli, S. C. (1999). Syndromes of abnormal fat redistribution and metabolic complications in HIV-infected patients. American Journal of Health-System Pharmacy, 56(22), 2343-2348.
144. Sullivan, A. K., Feher, M. D., Nelson, M. R., & Gazzard, B. G. (1998). Marked hypertriglyceridaemia associated with ritonavir therapy. AIDS, 12(11), 1393-1394.
145. Sullivan, A. K., & Nelson, M. R. (1997). Marked hyperlipidaemia on ritonavir therapy. AIDS, 11(7), 938-939.
146. Sullivan, A. K., Nelson, M. R., Moyle, G. J., Newell, A. M., Feher, M. D., & Gazzard, B. G. (1998). Coronary artery disease occurring with protease inhibitor therapy. International Journal of STD & AIDS, 9(11), 711-712.
147. Tebas, P., Powderly, W. G., Claxton, S., Marin, D., Tantisiriwat, W., Teitelbaum, S. L., et al. (2000). Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy [see comments]. AIDS, 14(4), F63-67.
148. Terry, L., Sprinz, E., & Ribeiro, J. P. (1999). Moderate and high intensity exercise training in HIV-1 seropositive individuals: A randomized trial. International Journal of Sports Medicine, 20(2), 142-146.
149. Thiebaut, R., Dabis, F., Malvy, D., Jacqmin-Gadda, H., Mercie, P., & Valentin Vd. (2000). Serum triglycerides, HIV infection, and highly active antiretroviral therapy, Aquitaine Cohort, France, 1996 to 1998. Groupe d'Epidemiologie Clinique du Sida en Aquitaine (GECSA). Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology, 23(3), 261-265.
150. Thomas, J. C., Lopes-Virella, M. F., Del Bene, V. E., Cerveny, J. D., Taylor, K. B., McWhorter, L. S., et al. (2000). Use of fenofibrate in the management of protease inhibitor-associated lipid abnormalities. Pharmacotherapy, 20(6), 727-734.
151. Thompson, C. J., Ryu, J. E., Craven, T. E., Kahl, F. R., & Crouse, J. R., III. (1991). Central adipose distribution is related to coronary atherosclerosis. Arteriosclerosis & Thrombosis, 11(2), 327-333.
152. Tran, Z. V., Weltman, A., Glass, G. V., & Mood, D. P. (1983). The effects of exercise on blood lipids and lipoproteins: A meta-analysis of studies. Medicine & Science in Sports & Exercise, 15(5), 393-402.
153. Treuth, M. S., Ryan, A. S., Pratley, R. E., Rubin, M. A., Miller, J. P., Nicklas, B. J., et al. (1994). Effects of strength training on total and regional body composition in older men. Journal of Applied Physiology, 77(2), 614-620. [Erratum appears in Journal of Applied Physiology 1994 Dec;77(6):following]
154. Tsiodras, S., Mantzoros, C., Hammer, S., & Samore, M. (2000). Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: A 5-year cohort study. Archives of Internal Medicine, 160(13), 2050-2056.
155. van der Valk, M., Gisolf, E. H., Reiss, P., Wit, F. W., Japour, A., Weverling, G. J., et al. (2001). Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection. AIDS, 15(7), 847-855.
156. Vergis, E. N., Paterson, D. L., Wagener, M. M., Swindells, S., & Singh, N. (2001). Dyslipidaemia in HIV-infected patients: Association with adherence to potent antiretroviral therapy. International Journal of STD & AIDS, 12(7), 463-468.
157. Walli, R., Herfort, O., Michl, G. M., Demant, T., Jager, H., Dieterle, C., et al. (1998). Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients. AIDS, 12(15), F167-F173.
158. Walli, R. K., Michl, G. M., Bogner, J. R., & Goebel, F. D. (2001). Improvement of HAART-associated insulin resistance and dyslipidemia after replacement of protease inhibitors with abacavir. European Journal of Medical Research, 6(10), 413-421.
159. Wanke, C., Gerrior, J., Kantaros, J., Coakley, E., & Albrecht, M. (1999). Recombinant human growth hormone improves the fat redistribution syndrome (lipodystrophy) in patients with HIV. AIDS, 13(15), 2099-2103.
160. Wensing, A. M., Reedijk, M., Richter, C., Boucher, C. A., & Borleffs, J. C. (2001). Replacing ritonavir by nelfinavir or nelfinavir/saquinavir as part of highly active antiretroviral therapy leads to an improvement of triglyceride levels. AIDS, 15(16), 2191-2193.
161. Wolfort, F. G., Cetrulo, C. L., Jr., & Nevarre, D. R. (1999). Suction-assisted lipectomy for lipodystrophy syndromes attributed to HIV-protease inhibitor use. Plastic & Reconstructive Surgery, 104(6), 1814-1820; discussion 1821-1812.
162. Yanovski, J. A. (1999). Endocrine and metabolic evaluation of human immunodeficiency virus-infected patients with evidence of protease inhibitor-associated lipodystrophy. Journal of Clinical Endocrinology & Metabolism, 84(6), 1925-1931.
163. Yarasheski, K. E., Tebas, P., Sigmund, C., Dagogo-Jack, S., Bohrer, A., Turk, J., et al. (1999). Insulin resistance in HIV protease inhibitor-associated diabetes. Journal of Acquired Immune Deficiency Syndromes, 21(3), 209-216.
164. Yarasheski, K. E., Tebas, P., Stanerson, B., Claxton, S., Marin, D., Bae, K., et al. (2001). Resistance exercise training reduces hypertriglyceridemia in HIV-infected men treated with antiviral therapy. Journal of Applied Physiology, 90(1), 133-138.
165. Yki-Jarvinen, H., & Koivisto, V. A. (1983). Effects of body composition on insulin sensitivity. Diabetes, 32(10), 965-969.